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CObjectives: To determine utility scores for health states relevant to the
treatment of early-stage, high-risk cervical cancer. Methods: Seven
descriptive health states incorporating the physical and emotional
aspects of medical treatment, recovery, and prognosis were devel-
oped. Forty-five female volunteers valuated each health state using
the visual analogue score (VAS) and time trade off (TTO) methods.
Treatment options were ranked by mean and median TTO scores.
The 95% confidence intervals were calculated to determine the sta-
tistical significance of ranking preferences. The Wilcoxon rank-sum test
was used to compare central tendencies related to age, race, parity, and
subject history of abnormal cervical cytology. Results: VAS and TTO
scores were highly correlated. Volunteers ranked minimally inva-
sive radical hysterectomy with low-risk features as most preferred
(mean TTO  0.96; median TTO  1.00) and aborted radical hyster-
ectomy followed by chemoradiation as least preferred (mean TTO 
0.69; median TTO 0.83). Health states that included radical surgery
ere ranked higher than those that included chemoradiation, either O
Kette
al So
doi:10.1016/j.jval.2010.11.017n the adjuvant or primary setting. When survival was comparable,
olunteers rated radical hysterectomy with high-risk pathology fol-
owed by adjuvant chemoradiation (mean TTO 0.78; median TTO
.92; 95% CI: 0.69–0.87) similarly to chemoradiation alone (mean
TO  0.76; median TTO 0.90; 95% CI: 0.66–0.86; p  NS). Utility
cores for the majority of health states were not significantly asso-
iated with age, race, parity, or subject history of abnormal cervical
ytology. Conclusion: Subjects consistently preferred surgical exci-
ion to treat early-stage, high-risk cervical cancer and chose a min-
mally invasive approach. Such utility scores can be used to incor-
orate quality-of-life effects into comparative-effectiveness models
or cervical cancer.
eywords: cervical cancer, cost analyses, treatment options, utility
cores.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Cervical cancer is the secondmost common cancer amongwomen
worldwide, with approximately 493,000 new cases and 274,000
deaths in 2009. Although cervical cytology screening programs
have steadily reduced the incidence of cervical cancer in devel-
oped countries, an estimated 11,270 women were diagnosed with
the disease and 4070 died from their disease in theUnited States in
2009 [1]. Women with early-stage cervical cancer have several
treatment options available, including radical hysterectomy
alone, radical hysterectomy followed by adjuvant chemoradiation
tailored to risk factors, chemoradiation alone, or neoadjuvant che-
motherapy followed by hysterectomy.
To date, no prospective randomized clinical trial has deter-
mined the “best” treatment option for patients with high-risk,
early-stage disease. Older, retrospective studies reported approx-
imately equal rates of cure using radical hysterectomy or primary
* Address correspondence to: Elizabeth L. Jewell, Memorial Sloan-
New York NY 10065 USA.
E-mail: jewelle@mskcc.org.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.radiotherapy [2–5]. Given similar rates of cure, treatments have
traditionally been based on physician preference [6–13]. Studies
over the past 10 years have demonstrated that the addition of
chemotherapy to radiotherapy reduces recurrence rates and im-
proves overall survival [10–12,14,15] and that an increasing num-
ber of patients may benefit from adjuvant chemoradiation [10].
Although many practitioners continue to favor surgery with tai-
lored chemoradiation based on pathologic risk factors such as pri-
mary treatment for high-risk, early-stage cervical cancer, con-
cerns regarding the cost and potential complications of
multimodality therapy have led some to question the need for
radical surgery [16].
In response to these issues, two groups have developed health
economic models to inform the treatment of stage IB2 cervical
cancer. Rocconi et al. [17] reported that radical hysterectomywas a
cost-saving strategy for IB2 cervical cancer, saving $500,000 to $2.2
million dollars per additional survivor. Jewell et al. [18] designed a
decisionmodel that incorporated the costs of both treatments and
ring Cancer Center, Gynecology Service, Department of Surgery,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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vant treatment ($27,840 per case for radical hysterectomy with
tailored adjuvant therapy) compared to primary radiotherapy
($21,403 per case for chemoradiation). Although this analysis did
not find that radical hysterectomy was cost saving, sensitivity
analysis showed that radical hysterectomy was potentially cost
effective (i.e., the cost per life-year saved was within the range
considered acceptable—approximately $50,000–75,000/life-year)
[18,19]. However, neither model incorporated quality of life (QOL)
measures. Cost-effectiveness models that lack consideration of
QOL may under- or overestimate the value of a given treatment
strategy. Utility scores are used to incorporate QOL effects into
cost-effectiveness analyses. Currently, there are no utility data for
treatment-related health states relevant to patients with cervical
cancer.
The objective of our study was to develop, using standard
methods for eliciting societal preferences, an instrument for the
derivation of utility values associated with cervical cancer treat-
ment.We estimated the perceived effect on QOL of surgical, radio-
therapeutic, and chemotherapeutic treatments, with specific at-
tention to both the usual physical and emotional effects, aswell as
estimated survival associated with each treatment scenario.
Methods
Health states: description
After Institutional Review Board approval was obtained, descrip-
tions of available treatment options for women with cervical can-
cer were created by two gynecologic oncologists (E.J. and L.H.).
These treatments included: radical hysterectomy with low-risk pa-
thology requiring no additional treatment; minimally invasive radi-
cal hysterectomy with low-risk pathology requiring no additional
treatment; radical hysterectomy with intermediate-risk pathology
with subsequent observation; radical hysterectomywith interme-
diate-risk pathology requiring adjuvant chemoradiation; radical
hysterectomy with high-risk pathology requiring chemoradiation
and outpatient brachytherapy; aborted radical hysterectomy with
chemoradiation and inpatient brachytherapy; and chemoradia-
tion (including teletherapy and brachytherapy) alone. Physical
and emotional aspects of each treatment were outlined and,
where appropriate, details about initial postoperative recovery,
outpatient whole pelvic radiation, outpatient chemotherapy, and
inpatient brachytherapy were described in the health state sce-
nario. Common side effects were incorporated into each descrip-
tion. Related to the phases of treatment, descriptive states were de-
veloped in which pathologic findings were known (as in the
treatment with radical hysterectomy) or unknown (such as when
treatment is by chemoradiation alone). Five-year survival informa-
tion was included in each health scenario.
Health states: focus group
A focus group composed of two additional gynecologic oncolo-
gists, two attending radiation oncologists, two gynecologic oncol-
ogy nurse clinicians, one oncology physician assistant, one clinical
social worker, and two cervical cancer survivors reviewed the
health state descriptions in detail andmade suggestions regarding
the severity or appropriateness of symptoms described as well as
their emotional consequences. The cervical cancer survivors par-
ticipating in the focus groupwere without evidence of disease and
had undergone surgery and/or chemoradiation. Edits to the health
state descriptions during this phase included the addition ofmore
specific descriptions of treatments, such as external beam radio-
therapy, specific physical symptoms, and physical limitations re-
lated to each treatment condition. This process resulted in a finalversion of the seven descriptive health states, which can be found
in Appendix A at doi:10.1016/j.jval.2010.11.017.
Health states valuation: recruitment of subjects
Forty-five members of the public were recruited using flyers in
various public places at our institution. Eligible patients were
English-speaking women who had no personal history of cervical
cancer. Due to limited funding, we were not able to translate con-
sents into Spanish or other languages. The decision to exclude
women with cervical cancer was based upon comments from cer-
vical cancer patients in the focus groupwho expressed discomfort
with the presentation of prognostic information. Subjects were
interviewed in an identical process in order to valuate health
states related to treatment of cervical cancer. A nominalmonetary
incentive was offered to offset travel expenses ($25) for 60 to 90
minutes of participation. All recruited subjects completed the
study.
Health states valuation: interview method
After obtaining informed consent and collecting demographic in-
formation, one of two trained research assistants interviewed vol-
unteers using the visual analogue score (VAS) and time trade off
(TTO)methods. The use of the TTOwas selected over the standard
gamble (SG) because the TTO is potentially less cognitively de-
manding for subjects. A potentially less difficult taskmay increase
the accuracy of the response. Additionally, the TTO method re-
quires a choice between certain health states; therefore, it mea-
sures the number of healthy years that are particular to a health
state. Such information is useful to measure health-related QOL.
For these reasons, the TTOmethodwas used [19]. Each subjectwas
asked to read a pertinent health state description and to listen
while it was read aloud. Health states were scored in a random
order. The subject then placed the health state on a continuum
(VAS) from 0 to 100, with 100 representing perfect health and 0
representing death. Each respondent made a mark on the VAS.
The scale contained no gradations other than 0 and 100. The VAS
was calculated as the distance from 0 to the mark placed by the
subject, divided by themeasure distance from 0 to 100 on the VAS.
The TTO interview was then administered as follows: the subject
was asked to assume a remaining life expectancy of 30 years, and
to choose between 30 years in the health state described or “X”
years in a state of perfect health. The utility of the health state, a
number between 0 and 1, was calculated as theminimumnumber
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Fig. 1 – Plot of median utility scores for visual analogue
score (VAS) and time trade off (TTO) for each treatment
health state. CR, chemoradiation; RH, radical hysterectomy.
584 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 8 2 – 5 8 6of years the patient would accept divided by 30. The 30-year time
horizon was chosen as a potentially meaningful life expectancy
because most cervical cancer patients are diagnosed between the
ages of 35 and 55. We acknowledge the limitation that the ages and
health states of subjectswith andwithout ahistory of cervical cancer
can vary significantly [19]. Treatment health states that included
prognostic information and 5-year survival information were only
valuated by volunteers without a history of cervical cancer. The ra-
tionale for this methodological decision was based upon comments
from cervical cancer patients in the focus group expressing discom-
fort with the survival information.
Statistics
SAS Version 9.2 (SAS Institute, Cary, NC) was used to perform the
analysis. Themean, standard deviation, median, and range of val-
ues for each health state for all 45 subjects were calculated. In this
research study, no anchor states were included to determine the
comprehension of the participants. Therefore, volunteer re-
sponses with the largest average absolute difference of VAS and
TTO scores were excluded from the analysis with the assumption
that such individuals did not understand the utility scoring exer-
cise. Five patients had a difference in their TTO and VAS score
greater than 50 and were excluded. Health states were ranked by
preference based on the mean and median. To determine the sta-
tistical difference in this scoring and ranking of health states, 95%
confidence intervals (CIs) of the mean TTO scores were provided.
TTO scores were used during this analysis since this choice-based
method provides an accurate assessment of the utility score
[19,20]. Wilcoxon rank sum tests were used to compare central
tendencies for each health state for subgroups (age dichotomized
at themedian) and likewise for parity (grouped as none, 1–2, more
than 2), race, and prior abnormal cervical cytology. The Spearman
correlation coefficient and P value were used to compare scores
Table 1 – Descriptive statistics of volunteers.
Volunteer characteristics
Age (years) 37.6 (19–61)
Race
White 21
Asian 5
African American 19
Prior abnormal Pap 18 (40%)
Gravidity, median (range) 2 (0–17)
Parity, median (range) 2 (0–12)
Table 2 – VAS and TTO scores for each treatment option.
Treatment scenario VAS
Mean Median SD Lower CI
Minimally invasive, low risk,
no adjuvant CR
0.79 0.86 0.17 0.74
RH, low risk, no adjuvant CR 0.82 0.88 0.18 0.76
RH, intermediate risk, no
adjuvant CR
0.72 0.77 0.20 0.66
RH, intermediate risk,
adjuvant CR
0.64 0.71 0.22 0.57
RH, high risk, adjuvant CR 0.62 0.65 0.24 0.55
CR 0.54 0.63 0.27 0.46
Aborted RH, followed by CR 0.46 0.46 0.24 0.39CI, confidence interval; CR, chemoradiation; RH, radical hysterectomy; SD,obtained using the two valuation methods (VAS and TTO) (Fig. 1).
The Spearman Correlation evaluated the relative similarity of util-
ity scoring using various methods of response: scaling (VAS) ver-
sus choice (TTO).
Results
All 45 recruited subjects completed the study. Themean age of the
subjects was 37.6 years (range, 19-61 years old). Nineteen subjects
were African American, 21 were white, and 5 were of Asian de-
scent. Forty percent of the volunteers had a history of abnormal
cervical cytology. Themedian parity for participants was 2 (range,
0–17). Subject characteristics are listed in Table 1.
For each health state, the mean TTO-derived utility score was
greater than the mean VAS-derived utility score. The Spearman
test indicated that all TTO and VAS scores were highly positively
correlated with each other (P  0.05). To test consistency of indi-
vidual scores between VAS and TTO, the absolute difference be-
tween VAS and TTO responses for each health state was calcu-
lated. The median absolute difference per health state was 24.3,
and the mean was 26.4 (range, 3.6-67.9). The responses of the
five subjects (10% of the volunteers) for whom the average dif-
ference in scores was greater than 50 were removed prior to the
analysis.
Utility scores for treatment of cervical cancer are listed in Table
2. The mean and median utility scores for health states requiring
adjuvant chemotherapy or radiation were consistently lower than
those for health states that only required surgery. The health state
describing a minimally invasive radical hysterectomy with low-
risk pathologic features wasmost preferred (TTO 0.95), whereas
an aborted radical hysterectomywith subsequent chemoradiation
including brachytherapy was least preferred (TTO  0.68). Any
completed radical hysterectomy was ranked higher than chemo-
radiation alone, regardless of 5-year survival information and sub-
sequent need for adjuvant chemoradiation.
Scores for the different health states (e.g., health states ranked
4–6 in Table 3) that included chemoradiation did not vary signifi-
cantly regardless of whether radical hysterectomy was performed
and prognosis was worse. The only statistically significant differ-
ence in utility scoreswas observed between the three health states
not requiring chemoradiation (95% CIs forminimally invasive rad-
ical hysterectomy with low-risk pathology/no adjuvant chemora-
diation, open radical hysterectomywith low-risk pathology/no ad-
juvant chemoradiation, and open radical hysterectomy with
intermediate-risk pathology/no adjuvant chemoradiation were
0.89–0.99, 0.82–0.97, and 0.82–0.96, respectively) and the health
TTO Spearman
correlation
coefficient
for VAS
and TTO
r CI Mean Median SD Lower CI Upper CI
4 0.96 1.00 0.12 0.92 1.00 .34
8 0.90 0.99 0.22 0.83 0.97 .44
8 0.90 0.97 0.21 0.83 0.97 .36
1 0.81 0.93 0.29 0.72 0.90 .56
9 0.78 0.92 0.31 0.69 0.87 .62
2 0.76 0.90 0.32 0.66 0.86 .69
3 0.69 0.83 0.35 0.58 0.80 .61Uppe
0.8
0.8
0.7
0.7
0.6
0.6
0.5standard deviation; TTO, time trade off; VAS, visual analogue score.
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585V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 8 2 – 5 8 6state describing an aborted radical hysterectomywith subsequent
chemoradiation (95% CI: 0.57–0.79; Table 3).
The results described above and their statistical significance
id not change when volunteers with an average absolute differ-
nce in VAS and TTO scoring greater than 50 were included in the
nalysis. When analyzing the effects of age, parity, race, and his-
ory of abnormal cervical cytology on the utility scores of treat-
ent-related health, no significant associations were observed.
Discussion
Comparative effectiveness analyses offer one way to examine op-
tions in the management of a disease. Cost-effectiveness models
determine the costs and outcomes associated with different man-
agement strategies by comparing cost per year of life saved. Mod-
els that incorporate QOL assessment in the form of utility scores
are called cost-utility analyses (CUAs). These models quantify im-
provements in survival, cost, and disease- and treatment-related
morbidity [20]. QOL is an important component of decisionmaking
in health care; researchers and clinicians are becoming more
aware of the need to obtain information about how the diagnosis
and treatment of disease affects the physical, mental, and social
well-being of patients. Studies assessing the cost and effective-
ness of specific interventions should also account for the changes
in QOL that are associated with each intervention and its known
adverse effects. CUA studies that report results in cost per quality-
adjusted life year are strongly recommended [19–21]. Our research
enhances the literature about social preferences in the treatment
of cervical cancer and can be used to inform future CUAs.
Our study is the first to report utility scores reflecting the fe-
male societal preference for current treatment options for early-
stage cervical cancer [22–32]. We found that health states describ-
ing chemoradiation were ranked lower than health states
describing surgery regardless of adjuvant chemoradiation. Even in
health scenarios with similar 5-year survival, subjects ranked sur-
gery followedby tailoredadjuvant treatmentasequivalentor slightly
preferred over primary chemoradiation. Based on the rankings of
treatment options, we hypothesize that there is a perceived benefit
to the physical removal of cancer. Subjects ranked aminimally inva-
sive approach highest, suggesting that an overnight hospitalization,
smaller incision sites, and faster return to activities of daily living are
preferred. Subjects also appeared to incorporate 5-year survival data
into their rankings, ranking aborted radical hysterectomy, with the
lowest survival estimate, as least preferred.
Other studies have examined QOL scores from the perspective
of women with cervical cancer. The aim of this study was to de-
velop utility scores assessing society’s preferences for treatment
options related to cervical cancer to be applied to cost-effective-
ness models. Interestingly, the societal health state preferences
identified in this study seem to be congruent with patient prefer-
ences reported in other studies. Frumovitz et al. [33] compared
OL and sexual functioning in cervical cancer survivors treated
Table 3 – Ranking of treatment-related health states by me
Rank Treatment Mean
1 Minimally invasive, low risk, no adjuvant CR 0.94
2 RH, low risk, no adjuvant CR 0.89
3 RH, intermediate risk, no adjuvant CR 0.89
4 RH, intermediate risk, adjuvant CR 0.80
5 RH, high risk, adjuvant CR, HDR brachy 0.78
6 CR 0.76
7 Aborted RH, followed by CR 0.68
CI, confidence interval; CR, chemoradiation; RH, radical hysterectomith either radical hysterectomy and lymph node dissection orradiotherapy. Cervical cancer survivors treated with radiotherapy
had worse QOL and sexual functioning than those treated with
radical hysterectomy and lymph node dissection [33]. These QOL
scores are in concordance with the current study, in which sub-
jects ranked surgery alone as preferred to chemoradiation alone.
Greimel et al. [34] investigated the long-term treatment side ef-
fects on the QOL and sexual functioning of cervical cancer survi-
vors and found that QOL scores of cervical cancer survivors who
underwent surgery and adjuvant radiation were significantly
lower than those of patients who had surgery alone. Similarly,
Distefano et al. [35] reported a better QOL in women with locally
advanced cervical cancer who received surgery alone. We sim-
ilarly found subjects preferred the single-treatment modality of
surgery over health states requiring adjuvant chemoradiation.
It is also interesting that subjects in this study ranked chemo-
radiation alone poorly; onemight predict that subjects would rank
this treatment as preferred over surgery, whichwould be followed
by chemoradiationwith its potential complications. In the current
study, however, the health states that incorporated chemoradia-
tion were more highly ranked if surgery was a component of the
treatment even if outcomeswere comparable [31–35]. It is possible
that the choice of the single-treatment modality of surgery over
chemoradiation may be related to the fear of radiation, anticipa-
tion of complications related to the combination of chemotherapy
and radiation, or merely a preference to have the tumor surgically
removed. It appeared that subjects werewilling to undergo radical
surgery and “risk” the need for adjuvant chemoradiation despite
the expectation of the side effects and prolonged treatment de-
tailed in the health state descriptions.
In the current study, several patients had large differences in
their rating of VAS-derived scores when compared with TTO-de-
rived scores for each health state. For example, one patient had a
mean VAS score of 0.03 for all health states evaluated, but a mean
TTO score of 1.0. An explanation for some of the differences be-
tween VAS and TTO scores may be the scoring method. VAS is a
scalingmethod, whereas TTO is a choicemethod that requires the
subject to conceptualize a tradeoff between quantity and QOL. It is
possible that a health state can be considered unpleasant, and so
worthy of a lower VAS score, but not so unpleasant as to compel a
trade off in life expectancy. Alternatively, those patients with the
largest difference between mean VAS- and TTO-derived scores
may have inadequately conceptualized the TTO method. Future
studies may benefit from exercises that assess whether a volun-
teer understands the TTO-scoring method by inclusion of graded
“anchor states.”
Our study had several limitations. The power of the study was
limited by the small sample size and the fact that some subjects
respondedwith awide discrepancy of scores. As a result, the stan-
dard deviation and range of responses for each health state was
broad. The study would have been strengthened by the inclusion
of a more diverse population, particularly the inclusion of Latina
women. Furthermore, the study focused on the acute postopera-
TO score with 95% CI.
SD Lower CI Upper CI Median Min Max
7.81 0.89 0.99 1.00 0.03 1.00
4.99 0.82 0.97 1.00 0.03 1.00
4.12 0.82 0.96 0.97 0.03 1.00
9.66 0.72 0.89 0.93 0.03 1.00
1.38 0.69 0.87 0.90 0.03 1.00
2.64 0.66 0.85 0.90 0.03 1.00
6.79 0.57 0.79 0.83 0.03 1.00
O, time trade off.an T
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586 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 8 2 – 5 8 6postoperative pain, prolonged bladder catheterization, acute diar-
rhea related to radiation therapies, and nausea and vomiting as-
sociated with chemotherapy; assumptions were made in the
health states that these symptoms resolved soon after the conclu-
sion of treatment. The omission of late and more severe compli-
cations associated with radical surgery and chemoradiation was
made in order to allow volunteers to score preferences on the
average experience of treatment itself, not on all potential adverse
events. Finally, our ranking of treatments was not derived using
womenwith cervical cancer, and therefore do not necessarily rep-
resent their preferences. While QOL from the perspective of the
individual patient is important and relevant, utility scores assess
society’s preferences, and it is therefore standard to derive these
using public volunteers unaffected by the disease. This allows for
utility scores to be used in health economic models that are de-
signed from the societal perspective [19].
Conclusion
In conclusion, we have established a pilot set of societal preferences
for health states related to the treatment of early-stage cervical can-
cer. This project expands the set of descriptive health states related
to gynecologic cancers and can be used to inform cost-effectiveness
models [18]. As the number of patients cured of their disease in-
creases, treatments with equivalent survival, similar cost, but better
QOL will surely be the optimal choice for patients.
Source of financial support: Financial support for this study
was provided entirely by a grant from the Charles Hammond Re-
search Fund.
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